Faiza Yasin, MD, MHS
Clinical FellowAbout
Research
Publications
2024
Molecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutations.
Yasin F, Sokol E, Vasan N, Pavlick DC, Huang RSP, Pelletier M, Levy MA, Pusztai L, Lacy J, Zhang JY, Ross JS, Cecchini M. Molecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutations. Oncologist 2024 PMID: 39401325, DOI: 10.1093/oncolo/oyae259.Peer-Reviewed Original ResearchUSPSTF Colorectal Cancer Screening Recommendation and Uptake for Individuals Aged 45 to 49 Years.
Siddique S, Wang R, Yasin F, Gaddy JJ, Zhang L, Gross CP, Ma X. USPSTF Colorectal Cancer Screening Recommendation and Uptake for Individuals Aged 45 to 49 Years. JAMA Netw Open 2024, 7: e2436358. PMID: 39361285, DOI: 10.1001/jamanetworkopen.2024.36358.Peer-Reviewed Original ResearchHydroxyurea in pregnancy: Reframing the conversation.
Yasin F, McGann P, Van Doren L. Hydroxyurea in pregnancy: Reframing the conversation. Am J Hematol 2024, 99: 1214-1216. PMID: 38546327, DOI: 10.1002/ajh.27299.Commentaries, Editorials and Letters
2021
High HIV Detection in a Tertiary Facility in Liberia: Implications and Opportunities
Ogbuagu O, Wachekwa I, Yasin F, Nuta C, Donato S, Toomey J, Adeiza M, Barakat LA. High HIV Detection in a Tertiary Facility in Liberia: Implications and Opportunities. Annals Of Global Health 2021, 87: 117. PMID: 34900617, PMCID: PMC8622250, DOI: 10.5334/aogh.3243.Peer-Reviewed Original ResearchConceptsHIV testing dataNon-pregnant individualsHIV detection rateTertiary facilityPrevention interventionsJohn F. Kennedy Medical CenterHospital-based retrospective analysisSignificant public health challengeStudy periodAnnual diagnosis ratePre-exposure prophylaxisPositive HIV testLarge tertiary hospitalCase detection ratePublic health challengeYears of ageNational prevalence estimatesDetection rateHIV/AIDSAntenatal clinicHIV testHIV testingTertiary hospitalPregnant womenUNAIDS 95Palliation of malignancies in HIV infection
Yasin F, Chow R, Emu B, Bui T, Prsic E. Palliation of malignancies in HIV infection. BMJ Supportive & Palliative Care 2021, bmjspcare-2021-003179. PMID: 34006512, DOI: 10.1136/bmjspcare-2021-003179.Peer-Reviewed Original Research
2020
Substantial gap in primary care: older adults with HIV presenting late to care
Yasin F, Rizk C, Taylor B, Barakat LA. Substantial gap in primary care: older adults with HIV presenting late to care. BMC Geriatrics 2020, 20: 438. PMID: 33129258, PMCID: PMC7603686, DOI: 10.1186/s12877-020-01842-y.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusCombination antiretroviral therapyViral suppressionCART initiationHIV clinicOlder patientsRetrospective medical record reviewHIV viral suppressionMedical record reviewPatient demographic dataSerious public health concernPublic health concernAntiretroviral therapyCD4 countHIV testingRecord reviewImmunodeficiency virusPrimary careOlder adult groupTreatment strategiesNew diagnosisAdvanced stagePatientsDemographic dataAdult groupCOVID-19 and the coming epidemic in US immigration detention centres
Meyer JP, Franco-Paredes C, Parmar P, Yasin F, Gartland M. COVID-19 and the coming epidemic in US immigration detention centres. The Lancet Infectious Diseases 2020, 20: 646-648. PMID: 32304631, PMCID: PMC7159863, DOI: 10.1016/s1473-3099(20)30295-4.Commentaries, Editorials and LettersHIV Update for the Primary Care Physician
Yasin, Faiza, 2020. HIV Update for the Primary Care Physician In Yale Office-based Medicine Curriculum, eds. Katherine A. Gielissen, Seonaid F. Hay, and Laura M. Whitman, 7th edition. New Haven, CT: Yale University.Peer-Reviewed Educational Materials
2019
Dolutegravir And Lamivudine Combination For The Treatment Of HIV-1 Infection
Zamora FJ, Dowers E, Yasin F, Ogbuagu O. Dolutegravir And Lamivudine Combination For The Treatment Of HIV-1 Infection. HIV/AIDS - Research And Palliative Care 2019, 11: 255-263. PMID: 31749636, PMCID: PMC6817767, DOI: 10.2147/hiv.s216067.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsHIV-1 infectionCombination antiretroviral therapyReverse transcriptase inhibitor lamivudineNucleoside reverse transcriptase inhibitor lamivudineSingle-tablet regimensTreatment-naive peopleTreatment of HIVClinical trial dataIntegrase inhibitor dolutegravirLong-term toxicityUnfavorable toxicity profileARV optionsEffective ARVAntiretroviral therapyLamivudine combinationInhibitor lamivudineToxicity profileRobust efficacyTrial dataDolutegravirInfectionDTG/3TCHIVTreatmentDrug development
2015
Technologies Global Health.
Ahn R, Kaonga N, Yasin F, Burke TF. Technologies Global Health. In: Nelson BD ed. Essential Clinical Global Health. West Sussex, UK: Wiley-Blackwell & Sons Ltd; 2015.Peer-Reviewed Original Research